Accepted Manuscript

Cargo-free particles of ammonio methacrylate copolymers: From pharmaceutical inactive ingredients to effective anticancer immunotherapeutics

Maryam Alsadat Shetab Boushehri, Valentin Stein, Alf Lamprecht

PII: S0142-9612(18)30153-4

DOI: 10.1016/j.biomaterials.2018.02.053

Reference: JBMT 18526

To appear in: Biomaterials

Received Date: 25 January 2018
Revised Date: 28 February 2018
Accepted Date: 28 February 2018

Please cite this article as: Boushehri MAS, Stein V, Lamprecht A, Cargo-free particles of ammonio methacrylate copolymers: From pharmaceutical inactive ingredients to effective anticancer immunotherapeutics, *Biomaterials* (2018), doi: 10.1016/j.biomaterials.2018.02.053.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



CCEPTED MANUSCRIPT

Cargo-free particles of ammonio methacrylate copolymers: from

pharmaceutical inactive ingredients to effective anticancer

immunotherapeutics

Maryam Alsadat Shetab Boushehri¹, Valentin Stein², Alf Lamprecht¹,

¹ Department of Pharmaceutics, University of Bonn, Bonn, Germany.

² Institute of Physiology, Medical Faculty, University of Bonn, Bonn, Germany.

³ Laboratory of Pharmaceutical Engineering (EA4267), University of Franche-Comté, Besançon, France.

Running headline: Potential role of ammonio methacrylate copolymer nanoparticles as cancer

immunotherapeutics

Abstract

Nanoparticles create exciting platforms for anticancer immunotherapy and vaccination, though

their inherent immunomodulatory properties have remained underexploited. Ammonio

methacrylate copolymers (AMC) are well-established excipients in pharmaceutical industry and

components of controlled-release oral formulations. Here, we demonstrate that nanoscaling of type

A and B AMC (Eudragit® RL and RS) endows these inactive ingredients immunostimulatory

properties exploitable for cancer therapy. The particles induce the secretion of various pro-

inflammatory cytokines and chemokines from the cells of innate immunity. Though the

underlying mechanisms are not fully uncovered, the current work established the partial

* Author of correspondence. Institute of Pharmacy, Department of Pharmaceutics, University of Bonn, Gerhard-Domagk-Str. 3, 53121

Bonn, Germany. Tel: +49 228 735233. Fax: +49 228 735268.

E-mail: alf.lamprecht@uni-bonn.de

1

Download English Version:

https://daneshyari.com/en/article/6484562

Download Persian Version:

https://daneshyari.com/article/6484562

<u>Daneshyari.com</u>